October 2013

Contents

Editorial

• Volume 14 Number 9/10 September/October 2013

Treatment alerts

• CROI website still blocked

Conference reports

• 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013, Denver

• Raltegravir safe and effective in pregnancy in small French study

• Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

• Good safety profile with long-acting integrase inhibitor GSK744

• TAF comparable to TDF in once-daily pill for ART-naive: 48-week results

• Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial

• 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

• High prices for antiretrovirals in middle-income countries outside Africa

• Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

• PrEP gives little extra benefit in attempted conception if male partner is on ART

Antiretrovirals

• Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US

• NHS England approves four-in-one Stribild (Quad) for limited use

• Dolutegravir approved in the US

• ViiV goes for gold: US premium pricing may make dolutegravir redundant in the UK

• From sky high to CHAI* – what needs to be done about dolutegravir pricing?

• Pharmacokinetics of etravirine with once-daily and twice-daily dosing

Treatment strategies

• Southern African treatment guidelines retain CD4 threshold of 350 for starting ART (2013)

Treatment access

• UK pledges £1 billion for Global Fund

• France pledges $1.4 billion for Global Fund

• UNAIDS reports new HIV infections are reduced by one-third compared to 2001

Side effects

• Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy

Hepatitis coinfection

• CID supplement on HCV and injecting drug users: free online issue

TB coinfection

• Activists call EU failure to approve delaminid for MDR tuberculosis due to limited data both “myopic and disappointing”

HIV prevention and transmission

• Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

• HIV self testing to become legal in the UK from April 2014

• Agreement to develop long-acting rilpivirine as PrEP

• Use of ART at baseline by treatment naïve patients in HPTN-052

Cure-related research

• Circulating memory T follicular helper cells correlate with the development of broadly neutralising antibody responses against HIV

Other news

• UK to lift ban on HIV positive health workers who are on ART with undetectable viral load

PDFs

• Volume 14 Number 9/10 September/October 2013 PDF